Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jill Lacy

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Clinical Advances in Hematology & Oncology : H&O|July 9, 2014
Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatmentsNatalia Neparidze, Jill Lacy
Journal of Neuro-Oncology|September 21, 2002
Case report: a patient with primary CNS lymphoma treated with temozolomide to complete responseKeith A Lerro, Jill Lacy
Clinical Medicine. Oncology|September 6, 2011
A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant GliomaTina Mayer, Jill Lacy, Joachim Baehring
Journal of the National Comprehensive Cancer Network : JNCCN|September 7, 2017
<i>EGFR</i> Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by <i>T790M</i>-Mediated ResistanceMichael Cecchini, Jeffrey Sklar, Jill Lacy
Hematology/Oncology Clinics of North America|July 17, 2012
Complications of brain tumors and their treatmentJill Lacy, Hamid Saadati, James B Yu
Clinical Genetics|December 11, 2024
Mismatch Repair Proficient Colorectal Adenocarcinoma in Two Patients With Lynch SyndromeBinny Khandakar, Jill Lacy, Joanna A Gibson
Experimental Hematology & Oncology|October 10, 2015
Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicityYue Zhang, Howard Hochster, Stacey Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximabRegina Loomis, Rocco Carbone, Michael Reiss, et al.
World Journal of Gastroenterology|March 12, 2008
Pseudocirrhosis in a pancreatic cancer patient with liver metastases: a case report of complete resolution of pseudocirrhosis with an early recognition and managementSoonmo Peter Kang, Tamar Taddei, Bruce McLennan, et al.
European Journal of Haematology|January 29, 2008
Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseasesPavani Srimatkandada, Regina Loomis, Rocco Carbone, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Clinical Advances in Hematology & Oncology : H&O|July 9, 2014
Malignancies associated with epstein-barr virus: pathobiology, clinical features, and evolving treatmentsNatalia Neparidze, Jill Lacy
Journal of Neuro-Oncology|September 21, 2002
Case report: a patient with primary CNS lymphoma treated with temozolomide to complete responseKeith A Lerro, Jill Lacy
Clinical Medicine. Oncology|September 6, 2011
A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant GliomaTina Mayer, Jill Lacy, Joachim Baehring
Journal of the National Comprehensive Cancer Network : JNCCN|September 7, 2017
<i>EGFR</i> Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by <i>T790M</i>-Mediated ResistanceMichael Cecchini, Jeffrey Sklar, Jill Lacy
Hematology/Oncology Clinics of North America|July 17, 2012
Complications of brain tumors and their treatmentJill Lacy, Hamid Saadati, James B Yu
Clinical Genetics|December 11, 2024
Mismatch Repair Proficient Colorectal Adenocarcinoma in Two Patients With Lynch SyndromeBinny Khandakar, Jill Lacy, Joanna A Gibson
Experimental Hematology & Oncology|October 10, 2015
Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicityYue Zhang, Howard Hochster, Stacey Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2003
Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximabRegina Loomis, Rocco Carbone, Michael Reiss, et al.
World Journal of Gastroenterology|March 12, 2008
Pseudocirrhosis in a pancreatic cancer patient with liver metastases: a case report of complete resolution of pseudocirrhosis with an early recognition and managementSoonmo Peter Kang, Tamar Taddei, Bruce McLennan, et al.
European Journal of Haematology|January 29, 2008
Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseasesPavani Srimatkandada, Regina Loomis, Rocco Carbone, et al.
Pageof 6